Search

Search Constraints

You searched for: Author/Creator Digiacomo, A.

Search Results

1. Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort. Issue 1 (February 2018)

2. Early occurrence of hepatocellular carcinoma (HCC) in patients with HCV cirrhosis treated with direct-acting antivirals (DAAs). Issue 1 (16th February 2017)

3. Efficacy of oral direct acting antivirals for treatment of advanced chronic hepatitis or compensated cirrhosis due to hepatitis C virus infection: The real-life experience of the Sicily registry. Issue 1 (16th February 2017)

4. Impact of age on viral kinetics of peginterferon alfa‐2a/ribavirin in chronic hepatitis C: final analysis from the PROPHESYS cohort. Issue 5 (17th October 2013)

5. Non-invasive tools to ruling out large varices: RESIST-HCV vs Baveno VI criteria in a large cohort of patients with HCV cirrhosis. Issue 1 (16th February 2017)

6. PC.01.10 LIVER AND CARDIOVASCULAR MORTALITY AFTER DAAS: DATA FROM THE RESIST-HCV COHORT. (25th March 2019)

7. Risk of hepatocellular carcinoma (HCC) recurrence in HCV cirrhotic patients treated with Direct Acting Antivirals (DAAs). Issue 1 (16th February 2017)

8. Second-generation DAAs for HCV: real-life efficacy in the RESIST-HCV cohort. (October 2019)

9. The prevalence of liver diseases due Hepatitis C Virus (HCV) in Sicily: A population-based survey. Issue 1 (16th February 2017)

10. Treatment of 320 genotype 3 cirrhotic patients with 12 weeks Sofosbuvir/Velpatasvir with or without ribavirin: real life experience from Italy. (February 2019)